热门资讯> 正文

Vir Biotechnology任命Aziz Sawaf为CFO

2026-10-01 20:38

Vir Biotechnology (VIR) has appointed Aziz Sawaf as executive vice president and chief financial officer, effective October 5, 2026, to lead the finance, IT, and investor relations functions.
Sawaf brings more than 20 years of biopharmaceutical experience spanning both large global organizations and small public biotechnology companies, the company said.
He joins Vir Biotechnology from Theravance Biopharma, where he served as CFO since 2023 and also as senior vice president of operations strategy since 2025, it added.
Source: Press Release

More on Vir Biotechnology

Vir Biotechnology: Astellas Deal Highlights The Platform's Value
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
Vir Biotechnology climbs 9% amid post-earnings uptrend
Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。